Invitae (NVTA) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 5 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued twelve-month price objectives for Invitae's stock. Their NVTA share price forecasts range from $1.50 to $8.00. On average, they anticipate the company's share price to reach $3.88 in the next twelve months. This suggests a possible upside of 226.3% from the stock's current price.
View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts.

Invitae's stock was trading at $1.86 at the beginning of 2023. Since then, NVTA shares have decreased by 36.0% and is now trading at $1.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our NVTA earnings forecast.

Invitae Co. (NYSE:NVTA) released its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The medical research company earned $117.36 million during the quarter, compared to analyst estimates of $116.57 million. Invitae had a negative net margin of 611.14% and a negative trailing twelve-month return on equity of 285.28%. The company's quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.78) EPS.

ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), AXS Green Alpha ETF (NXTE), Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC) and ARK Innovation ETF (ARKK).

Invitae updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00M-, compared to the consensus revenue estimate of $504.52 million.

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.78%), BlackRock Inc. (8.45%), Sumitomo Mitsui Trust Holdings Inc. (6.92%), Nikko Asset Management Americas Inc. (6.92%), Baker BROS. Advisors LP (3.41%) and State Street Corp (3.17%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends.

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $1.19.

Invitae (NYSE:NVTA) has a market capitalization of $310.20 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($13.32) on an earnings per share basis.

The company employs 1,700 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.